How Drug Stability Is Proven: ICH Q1 and the Science of Shelf Life

What an expiry date actually certifies

An expiry date is not a guess about when a medicine goes bad. It is a certified claim: the last day on which the manufacturer has generated evidence that the product still meets its approved specifications for identity, strength, quality, and purity, provided it was stored as the label instructs. Behind that single printed date sits months or years of laboratory work governed by an international rulebook. That rulebook is being rewritten. In 2025 the International Council for Harmonisation (ICH) released a draft guideline, ICH Q1, that consolidates decades of separate stability rules into a single document, and it changes how the science of shelf life will be documented worldwide.

Why one guideline replaced many

For more than twenty years, stability testing lived across a family of separate documents. The original ICH Q1A guideline, revised to Q1A(R2) and still hosted by the U.S. Food and Drug Administration, set the core expectations for new drug substances and products. Companion documents handled photostability, testing of new dosage forms, bracketing and matrixing designs, the definition of climatic zones, and evaluation of the resulting data. A parallel guideline, Q5C, covered biological products, which behave differently from small molecules.

The draft ICH Q1, which reached Step 2 of the ICH process and opened for public consultation from April to July 2025, gathers that scattered guidance, the Q1A through Q1F series plus Q5C, into one framework. According to the European Medicines Agency, which posts the draft for comment, the revision organizes stability expectations for both drug substances and drug products under shared, science- and risk-based principles. The point is coherence: one place to look, one vocabulary, and a single logic that spans conventional tablets, biologics, and newer therapy types rather than several overlapping texts written in different eras.

How stability is proven

Stability testing asks a simple question with demanding methods: how does the quality of a medicine change over time under defined conditions of temperature, humidity, and light? To answer it, samples are placed in tightly controlled chambers and pulled at intervals to measure whether the active ingredient is still present at the right strength, whether degradation products are forming, and whether the physical form still performs.

Two study types anchor the work. Long-term (real-time) testing stores the product under conditions meant to mirror normal storage and runs for the intended shelf life. Under the long-standing ICH parameters, that means a minimum of twelve months at 25 degrees Celsius and 60 percent relative humidity, or alternatively 30 degrees and 65 percent, with testing continued out to the full claimed duration. Accelerated testing deliberately stresses the product, classically a minimum of six months at 40 degrees Celsius and 75 percent relative humidity, to speed up chemical change and reveal vulnerabilities early. When the accelerated samples show a "significant change," meaning a pre-defined limit is crossed, that finding triggers testing at an intermediate condition and closer scrutiny before any shelf life can be claimed.

Real-time data ultimately sets the expiry date. Accelerated data supports it, allows limited and carefully justified extrapolation early in a product's life, and flags formulations that will not survive shipping or a hot warehouse.

What the new draft adds

The consolidated draft keeps this foundation and modernizes around it. A few themes stand out.

Modeling and prior knowledge

The draft explicitly encourages predictive stability modeling and the use of prior knowledge, so that established understanding of a molecule or platform can inform, though not replace, the required data. Statistical approaches to evaluating trends and estimating shelf life are given a clearer home. Used honestly, modeling can reduce redundant testing; used carelessly, it can overreach, which is why the draft frames these tools as justified additions to evidence rather than shortcuts around it.

In-use stability

Many medicines are not consumed the moment they are opened. A reconstituted antibiotic, a multi-dose eye drop, or an opened injectable pen faces a second clock once the seal is broken. In-use stability testing defines how long a product remains acceptable after first opening or reconstitution, which is the science behind those "use within 28 days of opening" instructions that patients actually rely on.

Efficient study design

The framework continues to support bracketing and matrixing, statistically sound designs that test a reasoned subset of samples, such as extreme strengths or container sizes, instead of every possible combination. Done properly, this trims testing burden without weakening the conclusion.

Why this matters to anyone who takes a medicine

The expiry date is one of the few pieces of pharmaceutical evidence a patient sees directly. Understanding what stands behind it clarifies two practical truths. First, the date is conditional: it assumes the storage the label specifies, which is why a drug left in a hot car or a humid bathroom may degrade ahead of schedule. Second, the date is a floor of assurance, not a cliff edge of danger, but it is the boundary of what has actually been demonstrated, and for products where potency loss carries real consequences that boundary deserves respect.

A single, harmonized guideline also matters at a systemic level. When regulators in different regions share one stability standard, the same evidence can support approval across markets, which reduces duplicated testing and supports steadier global supply of the medicines people depend on.

One point deserves emphasis: ICH Q1 is a draft. At Step 2 it is published for comment, not finalized, and its details can change before adoption and regional implementation. What is durable is the principle it formalizes. An expiry date is the visible endpoint of a hidden, rigorous chain of evidence, and knowing that chain exists is a small but real form of health literacy.

This article is educational and not medical advice.